Abstract
Amrubicin is a synthetic anthracyclin analogue that has significant activity in Japanese patients with extensive stage small cell lung cancer (ES-SCLC). There has not been significant advances made in the treatment of this disease in last several years and new therapies are desperately needed to change the natural history of this disease. Preliminary data has shown that amrubicin possesses anti-tumor activity in patients with extensive stage small cell lung cancer in the western population. Clinical trials are on going to evaluate this agent further in Europe and US. If effective, it may be an invaluable addition into the current armamentarium to treat this deadly disease. The review includes patent coverage on the treatment of small cell lung cancer.
Keywords: Amrubicin, small cell, lung cancer, chemotherapy, synthetic anthracyclin
Recent Patents on Anti-Cancer Drug Discovery
Title: Amrubicin: A Synthetic Anthracyclin Analogue in the Treatment of Extensive Stage Small Cell Lung Cancer
Volume: 4 Issue: 3
Author(s): Chirag M. Shah
Affiliation:
Keywords: Amrubicin, small cell, lung cancer, chemotherapy, synthetic anthracyclin
Abstract: Amrubicin is a synthetic anthracyclin analogue that has significant activity in Japanese patients with extensive stage small cell lung cancer (ES-SCLC). There has not been significant advances made in the treatment of this disease in last several years and new therapies are desperately needed to change the natural history of this disease. Preliminary data has shown that amrubicin possesses anti-tumor activity in patients with extensive stage small cell lung cancer in the western population. Clinical trials are on going to evaluate this agent further in Europe and US. If effective, it may be an invaluable addition into the current armamentarium to treat this deadly disease. The review includes patent coverage on the treatment of small cell lung cancer.
Export Options
About this article
Cite this article as:
Shah M. Chirag, Amrubicin: A Synthetic Anthracyclin Analogue in the Treatment of Extensive Stage Small Cell Lung Cancer, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (3) . https://dx.doi.org/10.2174/157489209789206850
DOI https://dx.doi.org/10.2174/157489209789206850 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PDE-5 Inhibitors for BPH-Associated LUTS
Current Drug Targets The DNA-Binding and Bioactivity of Rare Earth Metal Complexes
Mini-Reviews in Medicinal Chemistry Matrix Metalloproteinases in Respiratory Diseases: From Pathogenesis to Potential Clinical Implications
Current Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery The Significance of Transferrin Receptors in Oncology: the Development of Functional Nano-based Drug Delivery Systems
Current Drug Delivery Preface
Current Medical Imaging MiR-125b Inhibits Cell Proliferation and Induces Apoptosis in Human Colon Cancer SW480 Cells <i>via</i> Targeting STAT3
Recent Patents on Anti-Cancer Drug Discovery 3D-QSAR and Docking Studies on Pyrimidine Derivatives as CSF-1R Inhibitors
Letters in Drug Design & Discovery Application of CMB Model to PM10 Data Collected in a Site of South Italy: Results and Comparison with APCS Model
Current Analytical Chemistry Ponatinib: A Review of Efficacy and Safety
Current Cancer Drug Targets A Review on the Phytochemicals, Ethnomedicine Uses and Pharmacology of Ficus Species
Current Traditional Medicine Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry The Superior Antitumor Effect of Self-Assembled Paclitaxel Nanofilaments for Lung Cancer Cells
Current Drug Delivery Recent Progress in Liposome Production, Relevance to Drug Delivery and Nanomedicine
Recent Patents on Nanotechnology Molecular Mechanism of Resistance to Chemotherapy in Gastric Cancers, the Role of Autophagy
Current Drug Targets The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature Review
Current Drug Targets Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets Sphere Formation Assay is not an Effective Method for Cancer Stem Cell Derivation and Characterization from the Caco-2 Colorectal Cell Line
Current Stem Cell Research & Therapy Discovery and Hit to Lead Optimization of Novel Combretastatin A-4 Analogues: Dependence of C-Linker Length and Hybridization
Anti-Cancer Agents in Medicinal Chemistry